Evidence map›Paper›PMID 38766244›Full record

ArticlebioRxiv : the preprint server for biology2024

Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern.

Adonis A Rubio, Viren A Baharani, Bernadeta Dadonaite, Megan Parada, Morgan E Abernathy, Zijun Wang, Yu E Lee, Michael R Eso, Jennie Phung, Israel Ramos and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Adonis A RubioStanford Biosciences, Stanford School of Medicine; Stanford, USA.ORCID 0000-0003-3676-4283
Viren A BaharaniLaboratory of Retrovirology, The Rockefeller University; New York, USA.
Bernadeta DadonaiteBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center; Seattle, USA.
Megan ParadaDepartment of Biology, Stanford University; Stanford, USA.
Morgan E AbernathyDepartment of Biology, Stanford University; Stanford, USA.
Zijun WangLaboratory of Molecular Immunology, The Rockefeller University; New York, USA.
Yu E LeeDepartment of Biology, Stanford University; Stanford, USA.
Michael R EsoDepartment of Biology, Stanford University; Stanford, USA.
Jennie PhungDepartment of Biology, Stanford University; Stanford, USA.
Israel RamosDepartment of Biology, Stanford University; Stanford, USA.
Teresia ChenDepartment of Biology, Stanford University; Stanford, USA.
Gina El NesrStanford Biosciences, Stanford School of Medicine; Stanford, USA.ORCID 0000-0003-4857-9464
Jesse D BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center; Seattle, USA.ORCID 0000-0003-1267-3408
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University; New York, USA.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University; New York, USA.
Christopher O BarnesDepartment of Biology, Stanford University; Stanford, USA.

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
The Stanford-SLAC CryoEM Center supplementU24GM129541 · NIGMS · STANFORD UNIVERSITY · PI CHIU, WAH, HEDMAN, BRITT · 2018 to 2023
$54.8M
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Molecular Biophysics Training Program at StanfordT32GM136568 · NIGMS · STANFORD UNIVERSITY · PI Zev Bryant, KERWYN C. HUANG · 2021 to 2026
$3.7M
Prospectively characterizing the functional and antigenic effects of mutations to viral entry proteinsR01AI141707 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2018 to 2022
$2.1M
NCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI141707NIAID NIH HHS U19 AI057229NIGMS NIH HHS T32 GM136568NIGMS NIH HHS U24 GM129541
6 · The paper itself

Abstract

The ongoing emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the effectiveness of antibody therapeutics necessitates development of next-generation antibody modalities that are resilient to viral evolution. Here, we characterized N-terminal domain (NTD) and receptor binding domain (RBD)-specific monoclonal antibodies previously isolated from COVID-19 convalescent donors for their activity against emergent SARS-CoV-2 VOCs. Among these, the NTD-specific antibody C1596 displayed the greatest breadth of binding to VOCs, with cryo-EM structural analysis revealing recognition of a distinct NTD epitope outside of the site i antigenic supersite. Given C1596's favorable binding profile, we designed a series of bispecific antibodies (bsAbs) termed CoV2-biRNs, that featured both NTD and RBD specificities. Notably, two of the C1596-inclusive bsAbs, CoV2-biRN5 and CoV2-biRN7, retained potent

Identifiers

PMID38766244
PMCPMC11100608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.